{"id":47511,"date":"2022-08-22T12:02:12","date_gmt":"2022-08-22T10:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/radiopharmaceuticals-global-market-report-2022-radiopharmaceuticals-become-promising-for-cancer-theranostics-researchandmarkets-com\/"},"modified":"2022-08-22T12:02:12","modified_gmt":"2022-08-22T10:02:12","slug":"radiopharmaceuticals-global-market-report-2022-radiopharmaceuticals-become-promising-for-cancer-theranostics-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/radiopharmaceuticals-global-market-report-2022-radiopharmaceuticals-become-promising-for-cancer-theranostics-researchandmarkets-com\/","title":{"rendered":"Radiopharmaceuticals Global Market Report 2022: Radiopharmaceuticals Become Promising for Cancer Theranostics – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Radiopharmaceuticals – Global Market Trajectory & Analytics”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGlobal Radiopharmaceuticals Market to Reach US$8.9 Billion by the Year 2026<\/strong>\n<\/p>\n

\nGrowth in the global market is supported by growing number of nuclear procedures driven by rise in prevalence of cancer, and heart diseases. Significant therapeutic usage of radiopharmaceuticals became possible after the availability of cyclotrons and nuclear reactors which could synthesize large quantities of radioisotopes.\n<\/p>\n

\nThe market is further supported by the recent discovery of newer and successful therapeutic applications of radiopharmaceuticals in oncology and cardiology prognosis. Additional impetus from a stream of drug development and testing phases demonstrate the interest surrounding radiopharmaceuticals.\n<\/p>\n

\nDevelopment and progress in this space is anticipated to be fueled by immunology combined with radioisotopes and monoclonal antibodies so as to produce radioisotopes with unprecedented specificity in cancer diagnosis and therapy. Rising popularity of advanced SPECT\/CT and PET\/CT scanners is also expected to unravel new clinical opportunities. Rise in PET procedural volume is expected to provide opportunities for radiopharmaceuticals such as Fluorodeoxyglucose (FDG).\n<\/p>\n

\nAmid the COVID-19 crisis, the global market for Radiopharmaceuticals estimated at US$6.3 Billion in the year 2022, is projected to reach a revised size of US$8.9 Billion by 2026, growing at a CAGR of 8.7% over the analysis period.\n<\/p>\n

\nThe U.S. Market is Estimated at $3 Billion in 2022, While China is Forecast to Reach $545.7 Million by 2026<\/strong>\n<\/p>\n

\nThe Radiopharmaceuticals market in the U.S. is estimated at US$3 Billion in the year 2022. The country currently accounts for a 48% share in the global market. China, the world’s second largest economy, is forecast to reach an estimated market size of US$545.7 Million in the year 2026 trailing a CAGR of 11.3% through the analysis period.\n<\/p>\n

\nBeta Emitters Segment to Reach $1.6 Billion by 2026<\/strong>\n<\/p>\n

\nCertain radiopharmaceuticals consist of radionuclides that deliver particulate emission such as beta or alpha radiations or auger electrons possessing the capability to kill diseased tissues. In the global Beta Emitters segment, USA, Canada, Japan, China and Europe will drive the 10.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$744.7 Million will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$65.1 Million by the year 2026, while Latin America will expand at a 10.5% CAGR through the analysis period.\n<\/p>\n

\nSelect Competitors (Total 137 Featured):<\/strong>\n<\/p>\n